10 Università degli Studi di Milano - Divisione Stipendi e Carriere del Personale Ufficio Contratti di formazione e Ricerca Via Sant’Antonio 12 - 20122 Milano, Italia borse_assegni@unimi.it

TO MAGNIFICO RETTORE OF UNIVERSITA’ DEGLI STUDI DI MILANO ID CODE 3510

I the undersigned asks to participate in the public selection, for qualifications and examinations, for the awarding of a type B fellowship at Dipartimento di Scienze Biomediche e Cliniche “L. Sacco” Scientist- in – charge Prof.Enrico Mario Ferrazzi

Maria Luisa Ojeda Fernández

CURRICULUM VITAE

PERSONAL INFORMATION

Surname Ojeda Fernández

Name Maria Luisa

Date of birth 16-05-1979

PRESENT OCCUPATION

Appointment Structure

― ―

EDUCATION AND TRAINING

Degree Course of studies University year of achievement of the degree

Degree BS Biology Universitat Autònoma de Barcelona

2006

Degree BS Biochemistry Universitat Autònoma de Barcelona

2006

Specialization ―

PhD Cellular Biology and Genetics

Universidad Complutense de Madrid

2015

Master

Degree of medical specialization

Degree of European specialization

Other Type B cathegory diplome for animal experimentation

Accredited by FELASA (003/03), Madrid

2013

11 Università degli Studi di Milano - Divisione Stipendi e Carriere del Personale Ufficio Contratti di formazione e Ricerca Via Sant’Antonio 12 - 20122 Milano, Italia borse_assegni@unimi.it

REGISTRATION IN PROFESSIONAL ASSOCIATIONS

Date of registration

Association City

2010 Spanish Society of Biochemistry and Molecular Biology Madrid (Spain)

FOREIGN LANGUAGES

Languages level of knowledge

Spanish Mother tongue

Catalan Mother tongue

English Good

AWARDS, ACKNOWLEDGEMENTS, SCHOLARSHIPS

Year Description of award

2007 Public competition for a Pre-doctoral contract supported by “Centro de Investigación Biomédica en Red de Enfermedades Raras”, the Spanish Network for Biomedical Research in Rare Diseases.

TRAINING OR RESEARCH ACTIVITY

In July 2005 I initiated my research activity at the Center of Biological Research (Madrid), institute from the Spanish National Research Council (CSIC). The aim of the project was focused in the development of a mutant of human endoglin protein by direct mutagenesis. After my stay at the Center of Biological Research I obtained the degree in Biology and the degree in Biochemistry by the Universitat Autònoma de Barcelona (2006).

In June 2007 I obtained a public pre-doctoral contract from the Spanish Network of Rare Diseases focused on the research of Hereditary Haemorrhagic Telangiectasia (HHT), a vascular dysplasia with a prevalence of 1/5000-8000. The clinical features of HHT are epistaxis, mucocutaenous telangiectasies and arterio-venous malformations in internal organs (mainly liver, lung and brain).

I was responsible of samples management: human blood processing to obtain plasma samples and PBLs from healthy donors and HHT patients. I used plasma samples to evaluate the concentration of angiogenic soluble markers. I isolated DNA and RNA from PBLs for further analysis as the identification of mutations in ENG or ALK1 by Sanger technique or to conduct the expression analysis by whole genome DNA arrays (Affymetrix) or Q-PCR.

The analysis of plasma samples from HHT patients allowed us to establish a molecular diagnostic of HHT by the measurement of Ang-2 and sEng plasma levels with ELISA technique. One paper was published based on this project.

For other analysis and collaborations I developed the subsequent techniques: isolation of RNA from cultured PBLs, RT-PCR, DNA microarrays analysis of differential gene expression (FatiGO, Ingenuity), Q-PCR, Citokine/Chemokine quantifications by ELISA, Flow cytometry, Confocal microscopy, Immunohistochemistry, mouse handling and in vivo experiments.

In parallel, I performed a retrospective study of HHT patients clinical history to evaluate the incidence of immune disease in the HHT Spanish population and to establish a genotype-phenotype correlation, being also involved in the updating of our HHT patients database.

As a member of a research team specialized in a vascular dysplasia I collaborated in other projects as the evaluation of the effects of the transfection of miR205 in primary cultures of endothelial cells (HUVECs).

12 Università degli Studi di Milano - Divisione Stipendi e Carriere del Personale Ufficio Contratti di formazione e Ricerca Via Sant’Antonio 12 - 20122 Milano, Italia borse_assegni@unimi.it

I analyzed the effects of miR205 on the formation of tubular structures (matrigel matrix) and the migration of cultured endothelial cells. One paper was published based on this project.

In collaboration with the Pediatric Surgery Unit of the La Paz Hospital (Madrid) and with the Pediatrics Department of Nuevo Leon Hospital (Monterrey, México), I conducted the analysis of sEng plasma levels in pediatric patients with different vascular anomalies as infantile hemangioma, lymphatic and venous malformations.

PROJECT ACTIVITY

Year Project

2012-2014 Molecular basis for the pathogenicity of Hereditary Haemorrhagic Telangiectasia (HHT). Development of Pharmacological and Genetic based Cell therapies (SAF2011-23475). Funding agency: Ministerio de Ciencia e Innovacion (Spain).

2009-2012 Molecular and cellular mechanisms in chronic inflammatory and autoimmune diseases. Funding agency: Genoma Espana (MEICA).

2009-2011 Molecullar basis for the pathogenicity of the Hereditary Haemorrhagic Telangiectasia (HHT). Development of Pharmacological and Genetic based Cell therapies (SAF08-01218). Funding agency: Ministerio de Ciencia e Innovacion (Spain).

2007-2010 Therapeutic assays in cells derived from patients with Hereditary Haemorrhagic Telangiectasia (HHT) and genetic cell based therapy using endothelial progenitors cells in a mouse model of HHT. Funding agency: Ramon Areces Foundation (XIV Convocatoria de Ayudas a la Investigacion en Enfermedades Raras y Emergentes (Spain).

CONGRESSES AND SEMINARS

Date Title Place

9-10 March 2012

Vascular inflammation, aging and imaging. National Center of Cardiovascular Research. Madrid (Spain).

14-15 June 2010

Handling strategies for rare diseases. The experience of the Hereditary Hemorrhagic Telangiectasia Unit of the Sierrallana Hospital

International University Meméndez Pelayo. Santander (Spain).

21–22 April 2010

Introduction to the processment of research information from complex diseases

Lain Entralgo Agency (Madrid National Health System. Madrid (Spain).

19-21 May 2009

Workshop on design of FISH probes National Center of Oncology Research. Madrid (Spain).

12-13 November 2008

Angiogenesis and cancer: from basic mechanisms to therapeutic applications. International Symposium

Màalaga (Spain).

30 June – 1 July 2008

3rd International §Conference on Cell Therapy and Regenerative Medicine.

Barcelona (Spain).

23-26 June 2008

Basic Course of Analysis of DNA arrays data Parque Científico de Madrid Madrid (Spain).

10-14 March 2008

IV International Course of Microarray Data Analysis

Principe Felipe Research Institute. Valencia (Spain).

13 Università degli Studi di Milano - Divisione Stipendi e Carriere del Personale Ufficio Contratti di formazione e Ricerca Via Sant’Antonio 12 - 20122 Milano, Italia borse_assegni@unimi.it

June 2007 Laboratory Risk Prevention Course National Council of Scientific Research (CSIC). Madrid (Spain).

PUBLICATIONS

Articles in reviews

Ojeda-Fernández L, Recio-Poveda L, Aristorena M, Lastres P, Blanco FJ, Sanz-Rodríguez F, Gallardo-Vara E, de las Casas-Engel M, Corbí A, Arthur HM, Bernabeu C, Botella. Mice lacking endoglin in macrophages show an impaired immune response. PLoSGenetics. 2016 Mar 24;12(3):e1005935. PMID:27010826.

Zarrabeitia R, Ojeda-Fernández L, Recio L, Bernabéu C, Parra JA, Albiñana V, Botella LM. Bazedoxifene, a new orphan drug for the treatment of bleeding in hereditary haemorrhagic telangiectasia. Thromb Haemost. 2016 Jan 28;115(6). PMID: 26818701

Botella LM, Albiñana V, Ojeda-Fernández L, Recio-Poveda L, Bernabéu C. Research on potential biomarkers in hereditary hemorrhagic telangiectasia. Front Genet. 2015 Mar 31;6:115. PMID:25873934. REVIEW

Blanco FJ, Ojeda-Fernandez L, Aristorena M, Gallardo-Vara E, Benguria A, Dopazo A, Langa C, Botella LM, Bernabeu C. Genome-wide transcriptional and functional analysis of endoglin isoforms in the human promonocytic cell line U937. J Cell Physiol. 2015 Apr;230(4):947-58. PMID: 25216259.

Aristorena M, Blanco FJ, de Las Casas-Engel M, Ojeda-Fernandez L, Gallardo-Vara E, Corbi A, Botella LM, Bernabeu C. Expression of endoglin isoforms in the myeloid lineage and their role during aging and macrophage polarization. J Cell Sci. 2014 Jun 15;127(Pt 12):2723-35. PMID: 24777481.

Fontalba A, Fernández-Luna JL, Zarrabeitia R, Recio-Poveda L, Albiñana V, Ojeda-Fernández ML, Bernabéu C, Alcaraz LA, Botella LM. Copy number variations in endoglin locus: mapping of large deletions in Spanish families with hereditary hemorrhagic telangiectasia type 1. BMC Med Genet. 2013 Nov 25;14:121. PMID: 24267784.

Tabruyn SP, Hansen S, Ojeda-Fernández ML, Bovy N, Zarrabeitia R, Recio-Poveda L, Bernabéu C, Martial JA, Botella LM, Struman I. MiR-205 is downregulated in hereditary hemorrhagic telangiectasia and impairs TGF-beta signaling pathways in endothelial cells. Angiogenesis. 2013 Oct;16(4):877-87. PMID: 23800974.

Ojeda-Fernandez L, Barrios L, Rodriguez-Barbero A, Recio-Poveda L, Bernabeu C, Botella LM. Reduced plasma levels of Ang-2 and sEng as novel biomarkers in hereditary hemorrhagic telangiectasia (HHT). Clin Chim Acta. 2010 Apr 2;411(7-8):494-9. PMID: 20067780.

Fontalba A, Fernandez-L A, García-Alegria E, Albiñana V, Garrido-Martin EM, Blanco FJ, Zarrabeitia R, Perez-Molino A, Bernabeu-Herrero ME, Ojeda ML, Fernandez-Luna JL, Bernabeu C, Botella LM. Mutation study of Spanish patients with hereditary hemorrhagic telangiectasia. BMC Med Genet. 2008 Aug 1;9:75. PMID: 18673552.

Congress proceedings

“Bazedoxifene efficiency in the treatment of Hereditary Haemorrhagic Telangiectasia” VII CIBERER

Annual Meeting. Madrid (Spain). March, 2014. Selected for oral communication.

“Soluble Endoglin as marker of vascular anomalies in pediatric population” 1er Simposio en Investigación

Biomédica “Avances y perspectivas en Biomedicina Cardiovascular”. Madrid (Spain). March, 2014. Poster

communication.

“Immunological and allergic studies in HHT patients” VII National Meeting of the Spanish HHT

Association. Zaragoza (Spain). November, 2013. Oral communication.

Characterization of a myeloid specific endoglin knock-out mouse: the role of endoglin in the innate

immune response. 10th HHT Scientific Conference. Cork (Ireland). June 2013. Published in Hematology